Axovant Sciences (AXON) Hits New 52-Week High and Low at $1.11

Axovant Sciences (NASDAQ:AXON) hit a new 52-week high and low on Thursday . The company traded as low as $1.11 and last traded at $1.13, with a volume of 284498 shares trading hands. The stock had previously closed at $1.15.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 14th. Cowen reaffirmed a “hold” rating on shares of Axovant Sciences in a research note on Tuesday, February 13th. Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research note on Tuesday, February 13th. ValuEngine raised shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Chardan Capital raised shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price on the stock in a research note on Wednesday, January 10th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $13.61.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $127.19, a P/E ratio of -0.62 and a beta of -0.40. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 0.45.

In other Axovant Sciences news, Director George Bickerstaff purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were purchased at an average cost of $1.50 per share, with a total value of $37,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 72.40% of the company’s stock.

Several institutional investors have recently modified their holdings of AXON. Ameriprise Financial Inc. grew its holdings in shares of Axovant Sciences by 560.5% in the third quarter. Ameriprise Financial Inc. now owns 192,909 shares of the biotechnology company’s stock worth $1,327,000 after purchasing an additional 163,704 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Axovant Sciences by 135.6% in the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 30,905 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Axovant Sciences in the third quarter worth approximately $117,000. Hikari Power Ltd bought a new position in shares of Axovant Sciences in the fourth quarter worth approximately $377,000. Finally, BlackRock Inc. grew its holdings in shares of Axovant Sciences by 99.8% in the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after purchasing an additional 1,454,454 shares during the last quarter. Hedge funds and other institutional investors own 93.03% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Axovant Sciences (AXON) Hits New 52-Week High and Low at $1.11” was originally posted by Macon Daily and is the property of of Macon Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://macondaily.com/2018/04/19/axovant-sciences-axon-hits-new-52-week-high-and-low-at-1-11.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply